한
한상철 Chairman & CEO
C-suite M
KR KR · DART (FSS)
Browse the detailed record of transactions filed by 한상철, Chairman & CEO. Director active across 2 companies, notably 온코닉테라퓨틱스. In total, 5,725 filings have been logged. The latest transaction was disclosed on 4 March 2026 (Purchase). Regulator: DART (FSS). All data is openly available.
Declarations 5,725 total
€23,378 950 shares @ €24.608 0.0000% mcap 100.0% of flow
DART:20260515002789 · 8 May 2026
Executives ● PurchaseD DB증권 17 DART €7,973 1,000 shares @ €7.9729 0.0000% mcap 41.0% of flow
DART:20260515002900 · 14 May 2026
Ideal exit: 8 Feb 2027 (T+270) €3m 9,443 shares @ €297.3701 0.0000% mcap 7.5% of flow
DART:20260515002814 · 8 May 2026
Ideal exit: 2 Feb 2027 (T+270) €2m 1,293,660 shares @ €1.3566 0.0044% mcap 100.0% of flow
DART:20260515000829 · 8 May 2026
Ideal exit: 2 Feb 2027 (T+270) €58,186 7,900 shares @ €7.3654 0.0001% mcap 76.6% of flow
DART:20260515002070 · 11 May 2026
Executives ● Purchase휴 휴마시스 11 DART €879,604 381,422 shares @ €2.3061 0.0009% mcap 100.0% of flow
DART:20260515002044 · 13 May 2026
Ideal exit: 7 Feb 2027 (T+270) DART:20260515002905 · 15 May 2026 details not loaded
Executives ● Purchase유 유니크 24 DART €34,159 13,000 shares @ €2.6276 0.0000% mcap 13.8% of flow
DART:20260515001481 · 11 May 2026
Ideal exit: 5 Feb 2027 (T+270) Executives ● Purchase케 케이티 15 DART DART:20260515001559 · 15 May 2026
Ideal exit: 9 Feb 2027 (T+270) Executives ● Purchase앱 앱토크롬 2 DART DART:20260515001598 · 15 May 2026
Ideal exit: 9 Feb 2027 (T+270) Executives ● Purchase가 가온전선 14 DART €102,215 333 shares @ €306.9534 0.0000% mcap 51.8% of flow
DART:20260515001775 · 15 May 2026
Ideal exit: 9 Feb 2027 (T+270) Executives ● Purchase한 한솔홀딩스 28 DART €2,290 902 shares @ €2.5384 0.0000% mcap 33.1% of flow
DART:20260515001778 · 13 May 2026
Ideal exit: 7 Feb 2027 (T+270) Executives ● Sale앱 앱토크롬 2 DART DART:20260515001938 · 15 May 2026
Executives ● Sale파 파버나인 3 DART €2m 1,022,146 shares
DART:20260515001628 · 15 May 2026
Executives ● Purchase대 대성미생물 31 DART €11,719 3,000 shares @ €3.9062 0.0000% mcap 100.0% of flow
DART:20260515001671 · 15 May 2026
Ideal exit: 9 Feb 2027 (T+270) Executives ● Purchase가 가온전선 32 DART €95,971 280 shares @ €342.7547 0.0000% mcap 84.5% of flow
DART:20260515001848 · 15 May 2026
Ideal exit: 9 Feb 2027 (T+270) Executives ● Purchase휴 휴마시스 3 DART €872,947 381,422 shares
DART:20260515001992 · 15 May 2026
Ideal exit: 9 Feb 2027 (T+270) 256,792 shares
DART:20260515002117 · 15 May 2026
€5,357 37,366 shares @ €13.3926 0.0000% mcap 100.0% of flow
DART:20260515002263 · 31 Oct 2025
Executives ● Purchase유 유니크 20 DART €2,521 1,000 shares @ €2.5212 0.0000% mcap 100.0% of flow
DART:20260515001580 · 13 May 2026
Ideal exit: 7 Feb 2027 (T+270) Executives ● Purchase한 한솔홀딩스 5 DART €1,914 902 shares
DART:20260515002076 · 15 May 2026
Ideal exit: 9 Feb 2027 (T+270) Executives ● Sale하 하나투어 35 DART €120,702 5,000 shares @ €24.1404 0.0000% mcap 100.0% of flow
DART:20260515002262 · 7 May 2026
DART:20260515000127 · 15 May 2026 details not loaded
Executives ● Purchase일 일정실업 3 DART €90,204 66,919 shares
DART:20260515000220 · 15 May 2026
Ideal exit: 9 Feb 2027 (T+270) €7,984 880 shares @ €9.0732 0.0000% mcap 1.5% of flow
DART:20260515000306 · 12 May 2026
Ideal exit: 6 Feb 2027 (T+270) 25 of 5725 declarations
Load more (5700 remaining) About 한상철 Han Sang-cheol is the Chairman & CEO of Onconic Therapeutics, where he leads the company in developing innovative therapeutic solutions. With significant experience in the industry, he is responsible for overall strategy and operational direction. Han Sang-cheol is recognized for his ability to establish strategic partnerships and guide the company toward growth.